INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1

CUSIP: 45845PAB4

Q1 2021 13F Holders as of 31 Mar 2021

Type / Class
Debt / NOTE 2.000% 5/1
Market price (% of par)
64.82%
Total 13F principal
$225,406,985
Principal change
-$4,780,015
Total reported market value
$147,093,568
Number of holders
18
Value change
-$2,310,677
Number of buys
5
Number of sells
9

Quarterly Holders Quick Answers

What is CUSIP 45845PAB4?
CUSIP 45845PAB4 identifies 45845PAB4 - INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 as of Q1 2021

As of 31 Mar 2021, INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 was held by 18 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $225,406,985 in principal (par value) of the bond. The largest 10 bondholders included Kohlberg Kravis Roberts & Co. L.P., FRANKLIN RESOURCES INC, SOROS FUND MANAGEMENT LLC, LAZARD ASSET MANAGEMENT LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, FMR LLC, CONTRARIAN CAPITAL MANAGEMENT, L.L.C., MORGAN STANLEY, WOLVERINE ASSET MANAGEMENT LLC, and BNP PARIBAS ARBITRAGE, SA. This page lists 18 institutional bondholders reporting positions for the Q1 2021 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.